Key Market Indicators
Sales of antirheumatic medicines in Luxembourg are predicted to drop by 2.7% annually over the next five years, according to a new report. In 2021, Luxembourg had the 23rd highest sales of these medicines globally, at around $5 million. This was overtaken by Slovenia, whose sales reached $5.1 million. Germany, Spain and Canada were the second, third and fourth-ranked countries respectively. Since 2000, sales of antirheumatic medicines in Luxembourg have decreased by 5.2% each year. By 2026, the total is expected to reach around $4.4 million.
